Piper Sandler reiterated its Overweight rating on shares of Soleno Therapeutics Inc. (NASDAQ:SLNO) with a price target of $93.00. The firm's positive outlook is based on the anticipation of a favorable outcome for the company's drug candidate, DCCR, which is being developed for the treatment of Prader-Willi syndrome (PWS).
The firm's confidence in the drug is rooted in what it sees as a de-risked pathway for DCCR, leading up to a PDUFA date set for December 27, 2024. Analysts at Piper Sandler have conducted a thorough review of investor inquiries regarding the Advisory Committee (AdCom) meeting, including its timing, logistics, and the key topics that are expected to be addressed.
The analysis by Piper Sandler suggests that DCCR has a positive benefit/risk profile, supported by comprehensive data. The firm also notes that there is minimal regulatory risk involved due to the alignment between Soleno Therapeutics and regulatory authorities on the development plans for DCCR. This alignment has been further strengthened by precedents of other drugs that have been approved based on randomized withdrawal data.
The upcoming AdCom meeting is seen as a pivotal event for Soleno Therapeutics' stock, as it is expected to significantly influence the drug's approval process. Piper Sandler believes that the outcome of the AdCom meeting will likely correlate with the final approval decision.
If approved, DCCR is expected to be indicated for the treatment of PWS, specifically addressing hyperphagia in patients aged four years and older. The firm anticipates that the drug's clear safety profile and the high unmet medical need within this patient population will lead to strong market adoption.
In other recent news, Soleno Therapeutics has been in the spotlight with several significant developments. The company has submitted a New Drug Application (NDA) for its product DCCR, a potential treatment for Prader-Willi Syndrome, to the U.S. Food and Drug Administration (FDA). The FDA has granted Priority Review status to the application, with a Prescription Drug User Fee Act (PDUFA) target action date set for December 27, 2024.
Analysts from firms such as H.C. Wainwright, Stifel, and Oppenheimer have expressed optimism about the company's prospects. H.C. Wainwright initiated coverage with a Buy rating, while Stifel maintained a Buy rating, and Oppenheimer reiterated an Outperform rating. These firms anticipate a favorable outcome from the FDA's review process, highlighting the drug's potential market impact.
Soleno Therapeutics has seen significant changes in its Board of Directors, with Matthew Pauls stepping in as the new Lead Independent Director and biotech veteran Dawn Carter Bir joining the board. The company has also entered into an agreement with Jefferies LLC to potentially sell up to $150 million of its common stock, further strengthening its financial position.
Soleno Therapeutics has awarded performance-based restricted stock units to its employees, aligning their interests with the company's performance.
InvestingPro Insights
Soleno Therapeutics Inc. (NASDAQ:SLNO) presents an intriguing investment case, especially in light of the recent Piper Sandler analysis. According to InvestingPro data, the company's market capitalization stands at $1.9 billion, reflecting investor optimism about its potential. This optimism is further supported by the stock's impressive performance, with a 135.95% total return over the past year.
InvestingPro Tips highlight that Soleno's net income is expected to grow this year, and analysts predict the company will be profitable. These projections align well with Piper Sandler's positive outlook on DCCR's approval prospects and potential market adoption. Additionally, the company holds more cash than debt on its balance sheet, which could provide financial flexibility as it navigates the regulatory process and prepares for potential commercialization.
However, investors should note that Soleno is not currently profitable, with an adjusted operating income of -$68.5 million over the last twelve months. The stock's high Price/Book ratio of 6.75 suggests that market expectations are already quite elevated, which could be justified if DCCR receives approval and performs well in the market.
For those interested in a deeper analysis, InvestingPro offers 8 additional tips for Soleno Therapeutics, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.